Abstract:The identification of novel biomarkers and therapeutic targets in advanced cancer is critical for improving cancer diagnosis and therapeutics. Survivin (SV) is highly expressed predominantly in most cancer cells and tissues but is absent or undetectable in terminally differentiated normal adult tissues. Therefore, it functions as an almost universal tumor antigen. Peptides are short chains of amino acids linked by peptide bonds. To obtain novel SV decamers that are able to induce SV-specific cytotoxic T lymphocytes (CTLs) with a higher cytotoxic efficiency against cancer cells, major histocompatibility complex (MHC) peptide binding algorithms were conducted to predict nine modified SV95 decamers (from SV95–2 to SV95–10) based on the natural SV95–104 peptide sequence of ELTLGEFLKL (here defined as SV95–1). The fluorescent density of each SV95 peptide was determined by a MHC stability assay, followed by the generation of SV95-specific CTLs with each SV95 peptide (from SV95–1 to SV95–10) and human dendritic cells (DCs) loaded with Poly(lactic-co-glycolic) acid (PLGA) nanoparticles encapsulated with SV95 peptide. Finally, IFN-γ ELISpot and CytoTox 96® Non-Radioactive Cytotoxicity Assays were employed to verify their cytotoxic efficiency of the SV95-specific CTLs generated with the corresponding artificial antigen presenting cells (aAPCs) containing SV95 (SV95–1 to SV95–10) peptide. Furthermore, the cytotoxicity of the SV95 specific CTLs generated with nine mutated SV95 peptides was compared to the one generated with natural SV95–1 peptide and TIL2080 cells. The results indicated that the HLA-A2-restricted mutated SV95 epitope decamers (SV95–6 and SV95–7) showed significant higher binding ability compared to natural peptide SV95–1 in MHC stability assay. More importantly, SV95–specific CTLs with higher cytotoxicity were successfully induced with both SV95–6 and SV95–7 peptides, which significantly eliminated target cells (not only SV95–1 peptide pulsed T2 cells, but also both HLA-A2 and SV positive cancer cells) when compared to those generated with natural SV95–1 peptide and TIL2080 cells. These findings suggest that the SV95–6 and SV95–7 peptides are two novel HLA-A2-restricted CTL epitopes and may be useful for the immunotherapy for patients with survivin expressing cancer.

Disulfide Bond Cys30–cys299 and the Fragment “96rimqaplt106”of the Lid Region of Lip2 Are Critical for Its Biocatalytic Activity

[Anti-Prostate Cancer Activity of Survivin-T34A Mutant in Vitro and in Vivo].

High-level expression, purification and pro-apoptosis activity of HIV-TAT-survivin (T34A) mutant to cancer cells in vitro.

Construction, expression, and purification of HIV-TAT-survivin (T34A) mutant: a pro-apoptosis protein in Escherichia coli.

Preparation of Recombinant HIV-TATm-Survivin (T34A) Protein and Its Proapoptosis Activity to Four Cancer Cell Lines in vitro

Expression and Purification of Human Survivin Protein-Apoptosis Inhibitor in E. Coli TB1

Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs

Effects of recombinant protein TATm-Survivin(T34/117A) on cell cycle and apoptosis of B-Cap-37 cell

Value of Anti-Survivin in Early Diagnosis of Malignant Tumors

Effect on Apoptosis and Cell Cycle of Recombinant Double Negative Dominant Mutation Survivin (T34/117A) in Breast Cancer Cell B-Cap-37

Construction and Expression of Human Survivin and Preparation of Its Polyclonal Antibody

Novel Survivin Peptides Screened With Computer Algorithm Induce Cytotoxic T Lymphocytes With Higher Cytotoxic Efficiency to Cancer Cells

Antitumor Effect of Msurvivinthr34→ala in Murine Colon Carcinoma when Administered Intravenously.

Multiple targeting strategies achieve novel protein drug delivery into proapoptosis lung cancer cells by precisely inhibiting survivin

Development of A Fed-Batch Process for the Production of Anticancer Drug Tat(M)-Survivin(T34a) in Escherichia Coli

Characterization of the 12C4 Survivin Monoclonal Antibody and Insight into the Expression of Survivin in Human Adult Tissues.

Expression, purification and characterization of a novel triple fusion protein developed for the immunotherapy of survivin positive cancers

Prokaryotic expression of human survivin and preparation of anti-survivin monoclonal antibody

Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant

Expression of Survivin and Its Significance in Colorectal Cancer

Multisite mutation of monomer survivin with enhanced effect on apoptosis regulation of breast cancer cells.